This study aims to better understand the mechanisms by which Ebola virus infects cells and causes disease. To better understand the mechanisms by which Ebola virus infects cells and causes disease. Our laboratory is interested the basic biology underlying Ebola virus pathogenesis, virus-host interactions, and inhibition of virus replication. Ebola virus is a non-segmented negative strand RNA virus with a simple genome containing seven open reading frames. The virus replication cycle begins with binding of the envelope glycoprotein, GP, to a putative cell surface receptor(s) and entry into the host cell by fusion of viral and cell membranes. Strategies to interrupt the virus life cycle can be targeted to these early entry events or to later steps in the replication cycle. Our hypothesis is that molecular events underlying Ebola GP interactions within the host contribute to preferential targeting of Ebola virus infection to specific cell types, mediate pathogenic properties of the virus, and influence immune responses generated against the virus. Our goal with these studies is to identify points in the Ebola virus replication cycle that are vulnerable antiviral and neutralization targets. We are approaching this goal with several aims, each focusing on a particular aspect of GP function.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Intramural Research (Z01)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
United States
Zip Code
Oswald, Wendelien B; Geisbert, Thomas W; Davis, Kelly J et al. (2007) Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 3:e9
Martin, Julie E; Sullivan, Nancy J; Enama, Mary E et al. (2006) A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 13:1267-77
Yu, Jae-Sung; Liao, Hua-Xin; Gerdon, Aren E et al. (2006) Detection of Ebola virus envelope using monoclonal and polyclonal antibodies in ELISA, surface plasmon resonance and a quartz crystal microbalance immunosensor. J Virol Methods 137:219-28
Sullivan, Nancy J; Geisbert, Thomas W; Geisbert, Joan B et al. (2006) Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 3:e177
Chandran, Kartik; Sullivan, Nancy J; Felbor, Ute et al. (2005) Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308:1643-5
Jones, Steven M; Feldmann, Heinz; Stroher, Ute et al. (2005) Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11:786-90
Sullivan, Nancy J; Peterson, Mary; Yang, Zhi-yong et al. (2005) Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway. J Virol 79:547-53